Results for: InterCure

InterCure Ltd. (INCR) has demonstrated resilience in its first half of 2024 performance despite facing significant challenges, including disruptions at its southern Israeli facility. The company exceeded revenue estimates but continues to experience growth limitations due to the ongoing conflict. InterCure is investing heavily in restoring its facility and expects to return to full operational capacity in the coming quarters, aiming for double-digit sales growth in the second half of 2024.

InterCure, an Israeli-based cannabis operator, reported a decrease in revenue for the first half of 2024, citing damages to its southern facility caused by a terror attack. However, the company remains optimistic about future growth, highlighting its strategic partnerships, profitable operations, and ongoing facility restoration efforts.